IgM Autoantibodies Can Be Correlated in Cases of Atherosclerosis
|
By LabMedica International staff writers Posted on 20 Feb 2012 |
|
Low levels of immunoglobulin-M (IgM) autoantibodies against lipid phosphorylcholine (PC) add prognostic information in acute coronary syndromes (ACS).
The IgM autoantibodies can be easily measured by immunoassay and can be correlated with other known biomarkers in cases of atherosclerosis and other inflammatory diseases.
A team of scientists from the Karolinska Institutet (Stockholm, Sweden), collected and analyzed blood samples from 1,185 patients within 24 hours of admission between September 1995 and March 2001. Serum IgM anti-PC titers were measured by an enzyme-linked immunosorbent assay (ELISA) using a prototype of the Athera CVDefine kit. The assay is based on PCs covalently linked to bovine serum albumin coated onto 96-well microtiter plates. The detection limit was 0.5 U/L and coefficients of variation were less than 7%.
The results of the analysis showed that patients with low levels of anti-PC in connection with ACS and refractory, unstable angina run a greater risk of complications and premature death. The risk of death was more than double in coronary patients with low levels of anti-PC, who also had a significantly higher risk of additional heart attacks or other complications. The results also demonstrated for the first time that low anti-PC titers in ACS are associated with a considerably increased risk of a new acute cardiovascular event during several years, as well as increased mortality risk within, at least, the first 18 months after the primary ACS event. Low anti-PC titers may therefore represent a novel paradigm for reporting reduced atheroprotection in coronary vascular disease (CVD). The Athera CVDefine ELISA kit used in the study is a product of Athera Biotechnologies AB (Stockholm, Sweden).
Johan Frostegård, PhD, lead author and a professor at the Karolinska Institutet said, "The immunological treatment of cardiovascular diseases is clearly a Swedish specialty. Other Swedish researchers maintain that it's apolipoprotein B, an important constituent of LDL, that we should be vaccinating against, but the two aren't mutually exclusive and a combination is conceivable and something that we're now also testing." His team has spent many years developing immunological treatments for atherosclerotic plaque based on exploiting anti-PC to target phosphorylcholine. The study was published online on February 3, 2012, in the International Journal of Cardiology.
Related Links:
Karolinska Institutet
Athera Biotechnologies AB
The IgM autoantibodies can be easily measured by immunoassay and can be correlated with other known biomarkers in cases of atherosclerosis and other inflammatory diseases.
A team of scientists from the Karolinska Institutet (Stockholm, Sweden), collected and analyzed blood samples from 1,185 patients within 24 hours of admission between September 1995 and March 2001. Serum IgM anti-PC titers were measured by an enzyme-linked immunosorbent assay (ELISA) using a prototype of the Athera CVDefine kit. The assay is based on PCs covalently linked to bovine serum albumin coated onto 96-well microtiter plates. The detection limit was 0.5 U/L and coefficients of variation were less than 7%.
The results of the analysis showed that patients with low levels of anti-PC in connection with ACS and refractory, unstable angina run a greater risk of complications and premature death. The risk of death was more than double in coronary patients with low levels of anti-PC, who also had a significantly higher risk of additional heart attacks or other complications. The results also demonstrated for the first time that low anti-PC titers in ACS are associated with a considerably increased risk of a new acute cardiovascular event during several years, as well as increased mortality risk within, at least, the first 18 months after the primary ACS event. Low anti-PC titers may therefore represent a novel paradigm for reporting reduced atheroprotection in coronary vascular disease (CVD). The Athera CVDefine ELISA kit used in the study is a product of Athera Biotechnologies AB (Stockholm, Sweden).
Johan Frostegård, PhD, lead author and a professor at the Karolinska Institutet said, "The immunological treatment of cardiovascular diseases is clearly a Swedish specialty. Other Swedish researchers maintain that it's apolipoprotein B, an important constituent of LDL, that we should be vaccinating against, but the two aren't mutually exclusive and a combination is conceivable and something that we're now also testing." His team has spent many years developing immunological treatments for atherosclerotic plaque based on exploiting anti-PC to target phosphorylcholine. The study was published online on February 3, 2012, in the International Journal of Cardiology.
Related Links:
Karolinska Institutet
Athera Biotechnologies AB
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
New
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Latest Immunology News
- Novel Tool Uses Deep Learning for Precision Cancer Therapy
- Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients
- Novel Multiplex Assay Supports Diagnosis of Autoimmune Vasculitis
- Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer
- Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients
- Novel Gene Signature Predicts Immunotherapy Response in Advanced Kidney Cancers
- New Technology Deciphers Immune Cell Communication to Predict Immunotherapy Response
- AI Model Accurately Predicts MSI Tumor and Immune Checkpoint Inhibitor Responsiveness
- Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients
- Paper-Based Device Accurately Detects Immune Defects in 10 Minutes
- New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy
- Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer
- Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes
- World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment
- Blood Test Detects Organ Rejection in Heart Transplant Patients
- Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer
Channels
Clinical Chemistry
view channel
Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
Ovarian cancer is considered one of the deadliest cancers, in part because it rarely shows clear symptoms in its early stages, and diagnosis is often complex. Current approaches make it difficult to accurately... Read more
Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
Accurate cancer diagnosis remains a challenge, as liquid biopsy techniques often fail to capture the complexity of tumor biology. Traditional systems for isolating circulating tumor cells (CTCs) vary in... Read more
Molecular Diagnostics
view channel
2-Hour Cancer Blood Test to Transform Tumor Detection
Glioblastoma and other aggressive cancers remain difficult to control largely because tumors can recur after treatment. Current diagnostic methods, such as invasive biopsies or expensive liquid biopsies,... Read more
Automated High Throughput Immunoassay Test to Advance Neurodegenerative Clinical Research
Alzheimer’s disease and other neurodegenerative disorders remain difficult to diagnose and monitor accurately due to limitations in existing biomarkers. Traditional tau and phosphorylated tau measurements... Read more
Ultrasensitive Test Could Identify Earliest Molecular Signs of Metastatic Relapse in Breast Cancer Patients
HR+ (hormone receptor-positive) HER2- (human epidermal growth factor receptor 2-negative) breast cancer represents over 70% of all breast cancer cases and carries a significant risk of late recurrence.... Read more
Hematology
view channel
Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more
Platelets Could Improve Early and Minimally Invasive Detection of Cancer
Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more
Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more
Microbiology
view channel
Microfluidic Platform Assesses Neutrophil Function in Sepsis Patients
Sepsis arises from infection and immune dysregulation, with neutrophils playing a central role in its progression. However, current clinical tools are unable to both isolate these cells and assess their... Read more
New Diagnostic Method Confirms Sepsis Infections Earlier
Sepsis remains one of the most dangerous medical emergencies, often progressing rapidly and becoming fatal without timely intervention. Each hour of delayed treatment in septic shock reduces patient survival... Read more
New Markers Could Predict Risk of Severe Chlamydia Infection
Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more
Portable Spectroscopy Rapidly and Noninvasively Detects Bacterial Species in Vaginal Fluid
Vaginal health depends on maintaining a balanced microbiome, particularly certain Lactobacillus species. Disruption of this balance, known as dysbiosis, can increase risks of infection, pregnancy complications,... Read morePathology
view channel
Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma
Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more
Clinicopathologic Study Supports Exclusion of Cervical Serous Carcinoma from WHO Classification
High-grade serous carcinoma is a rare diagnosis in cervical biopsies and can be difficult to distinguish from other tumor types. Cervical serous carcinoma is no longer recognized as a primary cervical... Read more
Technology
view channel
Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine
The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Rapid Diagnostic Technology Utilizes Breath Samples to Detect Lower Respiratory Tract Infections
Respiratory tract infections (LRTIs) are leading causes of illness and death worldwide, particularly among vulnerable populations such as the elderly, young children, and those with compromised immune systems.... Read more
Industry
view channel
VedaBio Partners With Mammoth Biosciences to Expand CRISPR-Based Diagnostic Technologies
VedaBio (San Diego, CA, USA) has entered into a non-exclusive license agreement with Mammoth Biosciences (Brisbane, CA, USA) for the use of select CRISPR-based technologies in diagnostic applications.... Read more
